Eckert & Ziegler SE

Eckert & Ziegler raises its forecast for the current financial year once again

Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024

Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225

Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year

Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply

Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register

Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden

Eckert & Ziegler becomes European contract manufacturer for Telix’s innovative Phase III ProstACT GLOBAL study

Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024

Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area

Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.

Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism

Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility

Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA

Eckert & Ziegler receives “Best Managed Companies Award”

Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.

Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.

Eckert & Ziegler SE: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, buy